MedTrace Logo

Low Dose Atropine Eye Drops in Myopic Egyptian Children

NCT06265454 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-02-20

No results posted yet for this study

Summary

Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression.

purpose of the study is to compare changes in axial length, anterior chamber depth, choroidal thickness, central corneal thickness and anterior scleral thickness among myopic children receiving atropine 0.05% or 0.01% and placebo.

Conditions

  • Myopia Progression
  • Axial Length, Eye
  • Sclera Thickness

Interventions

DRUG

low dose atropine eye drops

Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Aya Mahmoud, Master's · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-12-30
Completion
2026-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06265454 on ClinicalTrials.gov